Search Results for: Clinical Roundup
-
MEI Pharma to Advance HDAC Inhibitor with $27.5M Raise
The company laid groundwork for clinical trials in advance of the financing and plans to begin a "very substantial" randomized Phase II study in the U.S...Results from a positive Phase I of ME-143 were presented at the American Society of Clinical Oncology meeting in June...Novelos plans to use the proceeds to complete an in-house clinical-stage manufacturing facility for its small-molecule, broad-spectrum, cancer-targeted imaging agent I-124-CLR1404 (LIGHTBy Marie Powers | BioWorld Today | Tuesday, November 6, 2012 -
Clinic Roundup
The clinical significance of those analyses is unknown. (See BioWorld Today, March 28, 2012BioWorld Today | Monday, November 5, 2012 -
Financings Roundup
Isconova AB, of Uppsala, Sweden, carried out a fully subscribed rights issue of about SEK50 million (US$7.4 million) to finance clinical trials in-house, increase production capacity and continue research in new indications for the adjuvant Matrix M. Shareholders representing 46.3 percent committed to subscribe for their respective pro rata share of the issue, with the remainder guaranteed by a consortiumBioWorld Today | Monday, November 5, 2012 -
Provenge Sales Disappoint, but Dendreon Shows Growth
We were losing a lot of patients to these clinical trials...I'm not satisfied with this performance and not looking at clinical trials as an excuse," Johnson said...Shares of Vertex (NASDAQ:VRTX) fell $5.47 to close at $45.01.By Catherine Shaffer | BioWorld Today | Monday, November 5, 2012 -
Supremes to Hear Arguments on 'Fraud-on-the-Market' Claims
They also identified differences in the toxic capabilities of three drugs in this class that are currently being investigated in clinical trials...The study, by scientists at the National Cancer Institute, and colleagues, appeared in Cancer Research.By Marie Powers | BioWorld Today | Monday, November 5, 2012 -
Earnings Roundup
The future growth of United's PAH franchise hit a snag late last month when its oral treprostinil candidate earned a complete response letter, with the FDA citing issues in the product's clinical data packageBioWorld Today | Friday, November 2, 2012 -
Financings Roundup
The funds will give the company enough runway to advance investigational lupus drug RSLV-132 into clinical trials, expected to begin in mid-2013BioWorld Today | Friday, November 2, 2012 -
Clinic Roundup
Study efficacy results demonstrated positive trends in slowing the rate of disease progression, ranging from 13 percent to 19 percent in multiple parameters of clinical benefit, although those pre-defined endpoints did not reach statistical significanceBioWorld Today | Friday, November 2, 2012 -
Financings Roundup
Integra focuses on biotech firms with products mostly in clinical developmentBioWorld Today | Thursday, November 1, 2012 -
Clinic Roundup
Muscle strength, clinical function and patient-reported outcomes also will be evaluated, though the study is not powered for those endpoints...two dose levels of active drug at four clinical sites in the U.SBioWorld Today | Wednesday, October 31, 2012 -
Hydrocodone Combo Products Come Under FDA Microscope
Thus, Calderon said she "would recommend requiring clinical studies to fully evaluate the abuse potential" of products submitted for review that exceed that levelBy Marie Powers | BioWorld Today | Monday, October 29, 2012 -
Clinic Roundup
Cytori Therapeutics Inc., of San Diego, said two independent investigator-sponsored and funded cell therapy clinical trials in Japan have been approved...Patients will be monitored for development of clinical symptoms and viral shedding...Initiation of the study followed a successful, dose-escalation Phase I study in which clinical activity was observed in five of seven patients receiving the two highest dose levelsBioWorld Today | Friday, October 26, 2012 -
No Bones About It: $35M Add Helps Drive Thrasos' AKI Drug
The company planned to switch from a bovine to a recombinant form of its AKI treatment, alkaline phosphatase. (See BioWorld Today, Sept. 14, 2011.) Bunnik, the Netherlands-based AM-Pharma had then gained only preliminary data from two small-scale clinical trials suggesting that bovine alkaline phosphatase improves kidney function and reduces the need for dialysis...Puma is working on neratinib, an oral, irreversible kinase inhibitor for HER2-posistive metastatic breast cancer. (See BioWorld TodayBy Randy Osborne | BioWorld Today | Friday, October 26, 2012 -
Clinic Roundup
Hadasit Bio-Holdings Ltd., of Jerusalem, said portfolio company Enlivex completed a 13-patient clinical trial of cellular treatment ApoCell for graft-vs.-host disease (GvHD), with results indicating efficacy and safety in recipients of bone marrow transplants from foreign donors...The primary endpoint of the 33-patient study is to determine the clinical benefit rate, while secondary objectives include progression-free survival and safety and tolerabilityBioWorld Today | Thursday, October 25, 2012 -
Bringing RNA Back, Mirna Gets $34.5M in Series C
Mirna will be the first company in clinical trials with a miRNA replacement therapy, and that fresh and different approach may have helped the company to attract its large, deep-pocketed investors...Shares of XOMA (NASDAQ:XOMA) fell 23 cents, to close at $2.99 Wednesday.By Catherine Shaffer | BioWorld Today | Thursday, October 25, 2012 -
Financings Roundup
The funds were raised from accredited investors and will be used to advance multiple clinical development programsBioWorld Today | Tuesday, October 23, 2012 -
Clinic Roundup
Derma Sciences Inc., of Princeton, N.J., said it plans to begin its Phase III program in December for DSC127, a clinical formulation of NorLeu3-A(1,7), in diabetic foot ulcers, to support the filing of a new drug applicationBioWorld Today | Tuesday, October 23, 2012 -
Pharma: Clinic Roundup
Investigators said 47 percent of patients receiving Simponi 50 mg and 51 percent of patients receiving Simponi 100 mg maintained clinical response through week 54 compared with 31 percent of patients on placebo (p = 0.01 and p < 0.001, respectively...Investigators will report clinical response, clinical remission and mucosal healing results through one year at the American College of Gastroenterology meeting in Las VegasBioWorld Today | Tuesday, October 23, 2012 -
Cat on a Hot Twin Proof? After Cougar, Puma Roars
The clinical relevance of neratinib as a 'pan-HER' family inhibitor and it being irreversible is yet to be proven," the paper said...Funds will be used to support the clinical development of cancer drugs aldoxorubicin and tamibarotene and for general corporate purposes, which could include working capital, capital expenditures, R&D and commercial activities.By Randy Osborne | BioWorld Today | Monday, October 22, 2012 -
Financings Roundup
Funds will be used to support the clinical development of cancer drugs aldoxorubicin and tamibarotene and for general corporate purposes, which could include working capital, capital expenditures, R&D and commercial activities...Net proceeds are expected to total $19.3 million and will be used for ongoing clinical development of dendritic cell-based vaccine ICT-107 and for general corporate purposesBioWorld Today | Friday, October 19, 2012
Category
Current Filters
- xNOT safety profile
Related Keywords
Categories
- x BioWorld Today (2288)
- x BioWorld International (51)
- x Bio Perspectives (3)
- x BioWorld Insight (2)
- x State of the Industry Report (2)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.